- Home
- IMG vs ABP Comparison
IMG vs ABP Comparison
Compare IMG & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMG
- ABP
- Stock Information
- Founded
- IMG 2011
- ABP 2004
- Country
- IMG Hong Kong
- ABP United States
- Employees
- IMG N/A
- ABP N/A
- Industry
- IMG
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- IMG
- ABP Health Care
- Exchange
- IMG NYSE
- ABP Nasdaq
- Market Cap
- IMG 14.7M
- ABP 15.5M
- IPO Year
- IMG 2020
- ABP N/A
- Fundamental
- Price
- IMG $0.27
- ABP $0.19
- Analyst Decision
- IMG
- ABP Strong Buy
- Analyst Count
- IMG 0
- ABP 1
- Target Price
- IMG N/A
- ABP $4.00
- AVG Volume (30 Days)
- IMG 237.8K
- ABP 5.8M
- Earning Date
- IMG 08-18-2025
- ABP 08-18-2025
- Dividend Yield
- IMG N/A
- ABP N/A
- EPS Growth
- IMG N/A
- ABP N/A
- EPS
- IMG N/A
- ABP N/A
- Revenue
- IMG $3,785,663.00
- ABP $183,000.00
- Revenue This Year
- IMG $99.05
- ABP N/A
- Revenue Next Year
- IMG $130.30
- ABP N/A
- P/E Ratio
- IMG N/A
- ABP N/A
- Revenue Growth
- IMG 109.62
- ABP 88.66
- 52 Week Low
- IMG $0.25
- ABP $0.15
- 52 Week High
- IMG $8.00
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- IMG N/A
- ABP N/A
- Support Level
- IMG N/A
- ABP N/A
- Resistance Level
- IMG N/A
- ABP N/A
- Average True Range (ATR)
- IMG 0.00
- ABP 0.00
- MACD
- IMG 0.00
- ABP 0.00
- Stochastic Oscillator
- IMG 0.00
- ABP 0.00
About IMG CIMG INC
CIMG Inc is a coffee and technologies company. The company is a co-packer of single-serve pour-over coffee, coffee brew bags and Dripkits. The company's brand portfolio includes Coffee Blenders, Twin Peaks, Active Cup, Relax Cup, Think Cup, Nude Cup, Pine Ranch Coffee, and Dripkit. Its geographical segments are North America, which accounts for the majority of revenue; and South Korea.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.